Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 boulevard de l'Hôpital, 75013 Paris, France.
Département d'Immunologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, 83 boulevard de l'Hôpital, 75013 Paris, France.
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.
Humoral immune responses are typically characterized by primary IgM antibody responses followed by secondary antibody responses associated with immune memory and composed of IgG, IgA, and IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of SARS-CoV-2-specific neutralizing antibodies in the serum, saliva, and bronchoalveolar fluid of 159 patients with COVID-19. Early SARS-CoV-2-specific humoral responses were dominated by IgA antibodies. Peripheral expansion of IgA plasmablasts with mucosal homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. The virus-specific antibody responses included IgG, IgM, and IgA, but IgA contributed to virus neutralization to a greater extent compared with IgG. Specific IgA serum concentrations decreased notably 1 month after the onset of symptoms, but neutralizing IgA remained detectable in saliva for a longer time (days 49 to 73 post-symptoms). These results represent a critical observation given the emerging information as to the types of antibodies associated with optimal protection against reinfection and whether vaccine regimens should consider targeting a potent but potentially short-lived IgA response.
体液免疫反应的特征通常是初次 IgM 抗体反应,随后是与免疫记忆相关的二次抗体反应,包括 IgG、IgA 和 IgE。在这里,我们测量了 159 名 COVID-19 患者的 SARS-CoV-2 急性体液免疫反应,包括血清、唾液和肺泡灌洗液中抗体分泌细胞的频率和 SARS-CoV-2 特异性中和抗体的存在。早期 SARS-CoV-2 特异性体液免疫反应以 IgA 抗体为主。在症状出现后不久,就检测到具有黏膜归巢潜力的 IgA 浆母细胞的外周扩张,并在疾病的第三周达到高峰。病毒特异性抗体反应包括 IgG、IgM 和 IgA,但与 IgG 相比,IgA 对病毒中和的贡献更大。症状出现后 1 个月,特异性 IgA 血清浓度明显下降,但中和性 IgA 在唾液中可检测到更长时间(症状后第 49 至 73 天)。鉴于有关与再感染最佳保护相关的抗体类型的信息不断涌现,以及疫苗方案是否应考虑针对有效但可能短暂的 IgA 反应,这些结果是一项重要观察。
Sci Transl Med. 2021-1-20
Sci Transl Med. 2021-1-20
J Allergy Clin Immunol. 2021-2
Antibodies (Basel). 2025-7-12
Front Immunol. 2025-6-11
Mol Ther Nucleic Acids. 2025-4-24
Sci Transl Med. 2021-1-20
EMBO J. 2020-11-4
Nature. 2020-5-26
Eur Respir J. 2020-8-27